Electrophysiological and behavioural evidence for an antagonistic modulatory role of adenosine A2A receptors in dopamine D2 receptor regulation in the rat dopamine‐denervated striatum
- 1 November 2000
- journal article
- research article
- Published by Wiley in European Journal of Neuroscience
- Vol. 12 (11) , 4033-4037
Abstract
It has been shown that striatal adenosine A2A receptors can antagonistically interact with dopamine D2 receptors at the membrane level leading to a decrease in the affinity and efficacy of D2 receptors. Extracellular recordings and rotational behaviour were employed to obtain a correlate to these findings in an animal model of Parkinson's disease (PD). The recordings were performed in rats with unilateral 6‐hydroxydopamine (6‐OHDA)‐induced catecholamine depletion. While recording in the dopamine‐depleted striatum, local applications of the dopamine D2 agonist quinpirole reduced neuronal activity. However, when the adenosine A2A antagonist MSX‐3 was applied simultaneously with quinpirole, the inhibition of neuronal firing seen after quinpirole alone was significantly potentiated (P < 0.001, n = 11). In contrast, local application of CGS 21680 attenuated the effect of quinpirole. The doses of MSX‐3 and CGS 21680 used to achieve the modulation of quinpirole action had no effect per se on striatal neuronal firing. Furthermore, rotational behaviour revealed that MSX‐3 dose‐dependently increased the number of turns when administrated together with a threshold dose of quinpirole while no enhancement was achieved when MSX‐3 was combined with SKF 38393. MSX‐3 alone did not induce rotational behaviour. In conclusion, this study shows that low ineffective doses of MSX‐3 enhance the effect of quinpirole on striatal firing rate, while the A2A agonist exerts the opposite action. This mechanism gives a therapeutic potential to A2A antagonists in the treatment of PD by enhancing D2 receptor function.Keywords
This publication has 25 references indexed in Scilit:
- A2A-selective adenosine receptor antagonists: Development of water-soluble prodrugs and a new tritiated radioligandDrug Development Research, 1998
- Adenosine A2A Antagonist: A novel antiparkinsonian agent that does not provoke dyskinesia in Parkinsonian monkeysAnnals of Neurology, 1998
- Adenosine–dopamine receptor–receptor interactions as an integrative mechanism in the basal gangliaTrends in Neurosciences, 1997
- Adenosine A2A receptor antagonists as new agents for the treatment of Parkinson's diseaseTrends in Pharmacological Sciences, 1997
- Dopamine D1 Receptor‐mediated Facilitation of GABAergic Neurotransmission in the Rat Strioentopeduncular Pathway and its Modulation by Adenosine A1 Receptor‐mediated MechanismsEuropean Journal of Neuroscience, 1996
- Blockade of A2a Adenosine Receptors Positively Modulates Turning Behaviour and c‐Fos Expression Induced by D1 Agonists in Dopamine‐denervated RatsEuropean Journal of Neuroscience, 1996
- Evidence for volume transmission in the dopamine denervated neostriatum of the rat after a unilateral nigral 6-OHDA microinjection. Studies with systemic d-amphetamine treatmentBrain Research, 1994
- Correlation of apomorphine- and amphetamine-induced turning with nigrostriatal dopamine content in unilateral 6-hydroxydopamine lesioned ratsBrain Research, 1993
- Striatal Restricted Adenosine A2 Receptor (RDC8) Is Expressed by Enkephalin but Not by Substance P Neurons: An In Situ Hybridization Histochemistry StudyJournal of Neurochemistry, 1991
- Function of intraventricular human mesencephalic xenografts in immunosuppressed rats: An electrophysiological and neurochemical analysisExperimental Neurology, 1991